Corvair vs Salix Coronary Plaque

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by AliveCor
VS
by Artrya

AI Verdict

Tool A (Corvair) specializes in AI-powered analysis of resting diagnostic ECGs, providing insights into the heart's electrical activity and rhythm. Tool B (Salix Coronary Plaque) focuses on AI-driven assessment of coronary artery plaque and stenosis using CCTA scans, offering detailed anatomical information on coronary artery disease. While both are cardiology AI tools, they utilize different diagnostic modalities and provide distinct types of information for cardiac assessment.

Choose Corvair if…

Choose Corvair if your primary need is AI-powered assistance for interpreting standard 10-second resting diagnostic ECGs. This tool is ideal for healthcare professionals in cardiology, emergency medicine, or internal medicine who require rapid, accurate analysis of cardiac rhythms and morphologies to enhance clinical confidence in ECG interpretation.

View Corvair →

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if you require advanced, AI-driven analysis of CCTA scans to assess coronary artery disease. This solution is best suited for cardiologists and radiologists focused on quantifying plaque burden, identifying high-risk plaque features, and evaluating stenosis in near real-time for comprehensive patient diagnosis.

View Salix Coronary Plaque →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Corvair Salix Coronary Plaque
Pricing Unknown Subscription model
Deployment Cloud, Mobile App Cloud-based (Amazon Web Services), web-based software application
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Corvair

Corvair's requirement for only 4 ECG leads for analysis significantly streamlines the data acquisition process, making it highly usable for rapid diagnostic assessments. While Salix offers an intuitive web-based interface and automated reporting, the inherent complexity of CCTA data analysis makes Corvair's simpler input a stronger point for overall usability.

Clinical Value

Salix Coronary Plaque

Salix Coronary Plaque offers a deeper and more specific clinical value by providing near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans. Its ability to identify high-risk plaque features, such as the 'napkin-ring sign,' provides critical, granular insights for diagnosing and stratifying coronary artery disease, which goes beyond the broad diagnostic assistance of ECG interpretation.

Pricing & Value

Salix Coronary Plaque

Salix Coronary Plaque offers superior transparency in its pricing model, explicitly stating a per-scan assessment model with a US CPT reimbursement rate of US$950. This clear pathway for revenue generation and cost recovery provides a tangible value proposition that is absent from Corvair's 'contact vendor' pricing.

Enterprise Readiness

Corvair

Corvair explicitly states its HIPAA compliance, availability of a Business Associate Agreement (BAA), and ISO 42001 certification for its AI Management System. These documented assurances of data security, privacy, and AI governance provide a stronger foundation for enterprise readiness compared to Salix, which lacks explicit statements on BAA and HIPAA compliance in the provided information.

Innovation

Salix Coronary Plaque

Salix Coronary Plaque demonstrates greater innovation by applying AI to CCTA scans for near real-time, point-of-care assessment of complex coronary plaque features, including high-risk indicators like the 'napkin-ring sign'. This detailed plaque characterization represents a more advanced and novel application of AI in cardiovascular diagnostics compared to general ECG interpretation.

Support & Docs

Tie

Both companies, as providers of FDA-cleared medical software, are expected to offer comprehensive support and documentation for their professional products. Web searches indicate that both AliveCor and Artrya provide dedicated customer support, training, and user manuals, but there is insufficient detail to differentiate between the two in terms of the quality or extent of these offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Corvair Salix Coronary Plaque
Name Corvair Salix Coronary Plaque
Company AliveCor Artrya Limited
Description FDA-cleared AI ECG analysis system that assists healthcare professionals in interpreting resting diagnostic ECGs with 35 cardiac determinations. FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease.
Primary Analysis Type ECG analysis (10-second ECGs) CCTA analysis (coronary artery plaque and stenosis)
Key Output/Determinations 35 cardiac determinations (14 rhythm, 21 morphology) Detection and quantification of coronary plaque, identification of high-risk plaque features, stenosis assessment, quantification of calcifications (calcium scoring)

Videos

Demos, reviews, and walkthroughs featuring Corvair and Salix Coronary Plaque.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Corvair by AliveCor is designed to analyze 10-second resting diagnostic ECGs, providing interpretations based on electrical activity of the heart. In contrast, Artrya Salix Coronary Plaque analyzes CCTA (Coronary Computed Tomography Angiography) scans, which are imaging studies that visualize the coronary arteries.
Corvair assists healthcare professionals in interpreting ECGs by providing 35 cardiac determinations, including 14 rhythm and 21 morphology determinations. Artrya Salix Coronary Plaque focuses on detecting and quantifying coronary artery plaque and stenosis from CCTA scans, identifying high-risk plaque features, and quantifying calcifications (calcium scoring) to aid in diagnosing coronary artery disease.
Corvair is intended for use by healthcare professionals in Cardiology, Emergency Medicine, and Internal Medicine. Artrya Salix Coronary Plaque is primarily aimed at Cardiology and Radiology specialists.
Corvair's output consists of an automated interpretation of ECGs with 35 cardiac determinations, which can then be reviewed by a healthcare professional. Artrya Salix Coronary Plaque generates automated reports with detailed quantification of coronary plaque, assessment of stenosis, identification of high-risk plaque features like low-attenuation plaque and napkin-ring sign, and calcium scoring from CCTA scans.
Both Corvair and Artrya Salix Coronary Plaque are FDA-cleared. Corvair is explicitly stated as HIPAA compliant with a Business Associate Agreement (BAA) available and is ISO 42001 certified for its AI Management System. Artrya Salix Coronary Plaque's HIPAA compliance and BAA are not explicitly stated for the product in the provided information, though BAAs are generally expected for healthcare AI in the US market.
For Artrya Salix Coronary Plaque, there is a stated US CPT reimbursement rate of US$950 per assessment, with a per-scan assessment model. Pricing for Corvair is listed as 'contact vendor,' with no specific reimbursement information provided.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.